お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
967909

自己免疫疾患治療の世界市場

Autoimmune Disorder Therapies: Global Markets

出版日: | 発行: BCC Research | ページ情報: 英文 156 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.53円
自己免疫疾患治療の世界市場
出版日: 2020年10月26日
発行: BCC Research
ページ情報: 英文 156 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の自己免疫疾患治療の市場規模は、2019年に532億米ドルとなりました。同市場は、2019年から2024年の間に11.2%のCAGRで成長する見通しで、2024年には907億米ドルに達すると予測されています。また、セグメント別では、免疫抑制薬市場は12%、NSAID(非ステロイド性抗炎症薬)市場は9.6%のCAGRで予測期間中に成長する見込みです。

当レポートは、世界の自己免疫疾患治療市場について調査しており、市場規模や予測、機会、成長および抑制要因、COVID-19の影響、医薬品クラス・適応症・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 イントロダクション

第2章 結論とハイライト

第3章 市場と技術の背景

  • 自己免疫疾患治療
  • 自己免疫疾患治療としての生物学
  • 自己免疫疾患治療の動向

第4章 市場力学

  • 市場の成長要因
  • 市場の抑制要因
  • 市場機会

第5章 市場分析:医薬品クラス別

  • 世界市場
  • NSAID
  • 免疫抑制薬

第6章 市場分析:適応症別

  • 世界市場
  • 1型糖尿病
  • 関節リウマチ
  • 乾癬/乾癬性関節炎
  • 多発性硬化症
  • 炎症性腸疾患
  • 全身性エリテマトーデス
  • その他

第7章 市場分析:地域別

  • 世界市場
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 COVID-19の影響

第9章 治療パイプライン

第10章 競合情勢

  • 世界の企業シェア分析
  • 合併と買収
  • 契約、ローンチ、協業、提携

第11章 企業プロファイル

  • ABBVIE INC.
  • AMGEN INC.
  • ASTRAZENECA
  • BAYER AG
  • BRISTOL-MYERS SQUIBB
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON
  • MYLAN N.V.
  • NOVARTIS AG
  • PFIZER INC.
  • VERTEX PHARMACEUTICALS INC.

第12章 付録:略語

図表

List of Tables

  • Summary Table B: Global Market for Autoimmune Disorder Therapies, by Indication, Through 2024
  • Summary Table A: Global Market for Autoimmune Disorder Therapies, by Drug Class, Through 2024
    • Table 1: Biologics as Autoimmune Disorder Therapies
    • Table 2: Effect of Some Autoimmune Disease Drugs on the Clinical Course of Patients with COVID-19
    • Table 3: Global Market for Autoimmune Disorder Therapies, by Drug Class, Through 2024
    • Table 4: Global Market for NSAIDs for Autoimmune Disorder Therapies, by Region, Through 2024
    • Table 5: Global Market for Immunosuppressant Drugs for Autoimmune Disorder Therapies, by Region, Through 2024
    • Table 6: Therapeutic Effects of Glucocorticoids
    • Table 7: Global Market for Corticosteroids for Autoimmune Disorder Therapies, by Region, Through 2024
    • Table 8: Global Market for Biologics for Autoimmune Disorder Therapies, by Region, Through 2024
    • Table 9: Global Market for Inhibitors for Autoimmune Disorder Therapies, by Region, Through 2024
    • Table 10: Global Market for Autoimmune Disorder Therapies, by Indication, Through 2024
    • Table 11: Global Market for Autoimmune Disorder Therapies for Type 1 Diabetes, by Region, Through 2024
    • Table 12: Global Market for Autoimmune Disorder Therapies for Rheumatoid Arthritis, by Region, Through 2024
    • Table 13: Global Market for Autoimmune Disorder Therapies for Psoriasis/Psoriatic Arthritis, by Region, Through 2024
    • Table 14: Drugs in the Pipeline for Psoriatic Disease
    • Table 15: Global Market for Autoimmune Disorder Therapies for Multiple Sclerosis, by Region, Through 2024
    • Table 16: Global Market for Autoimmune Disorder Therapies for Inflammatory Bowel Disease, by Region, Through 2024
    • Table 17: Global Market for Autoimmune Disorder Therapies for Systemic Lupus Erythematosus, by Region, Through 2024
    • Table 18: Global Market for Autoimmune Disorder Therapies for Other Autoimmune Diseases, by Region, Through 2024
    • Table 19: Global Market for Autoimmune Disorder Therapies, by Region, Through 2024
    • Table 20: North American Market for Autoimmune Disorder Therapies, by Drug Class, Through 2024
    • Table 21: North American Market for Autoimmune Disorder Therapies, by Indication, Through 2024
    • Table 22: North American Market for Autoimmune Disorder Therapies, by Country, Through 2024
    • Table 23: European Market for Autoimmune Disorder Therapies, by Drug Class, Through 2024
    • Table 24: European Market for Autoimmune Disorder Therapies, by Indication, Through 2024
    • Table 25: European Market for Autoimmune Disorder Therapies, by Country, Through 2024
    • Table 26: Asia-Pacific Market for Autoimmune Disorder Therapies, by Drug Class, Through 2024
    • Table 27: Asia-Pacific Market for Autoimmune Disorder Therapies, by Indication, Through 2024
    • Table 28: Asia-Pacific Market for Autoimmune Disorder Therapies, by Country, Through 2024
    • Table 29: Rest of World Market for Autoimmune Disorder Therapies, by Drug Class, Through 2024
    • Table 30: Rest of World Market for Autoimmune Disorder Therapies, by Indication, Through 2024
    • Table 31: Rest of World Market for Autoimmune Disorder Therapies, by Country/Region, Through 2024
    • Table 32: Pharmaceutical Companies Involved in COVID-19 Testing and Research
    • Table 33: Anti-TNF Biosimilars and Others in the Development for the Treatment of Autoimmune Inflammatory Diseases
    • Table 34: AbbVie Inc.: Product Portfolio
    • Table 35: Amgen Inc.: Product Portfolio
    • Table 36: AstraZeneca: Product Portfolio
    • Table 37: Bayer AG: Product Portfolio
    • Table 38: Bristol-Myers Squibb: Product Portfolio
    • Table 39: F. Hoffmann-La Roche & Co.: Antibiotics Product Portfolio
    • Table 40: Johnson & Johnson: Product Portfolio
    • Table 41: Mylan N.V.: Product Portfolio
    • Table 42: Novartis AG: Product Portfolio
    • Table 43: Pfizer Inc.: Product Portfolio
    • Table 44: Pfizer Inc.: Pipeline Product Portfolio
    • Table 45: Vertex Pharmaceuticals Inc.: Antibiotics Product Portfolio
    • Table 46: Acronyms Used in This Report

List of Figures

  • Summary Figure A: Global Market for Autoimmune Disorder Therapies, by Drug Class, 2018-2024
  • Summary Figure B: Global Market Share of Autoimmune Disorder Therapies, by Indication, 2019
    • Figure 1: Prevalence of Diagnosed Autoimmune Conditions in Selected Countries, 2019
    • Figure 2: Deaths Due to Diabetes in Adults, by Age Group and Sex, 2019
    • Figure 3: Number of Diabetes Patients (Ages 20-79 years), Projection and Trends, 2000-2045
    • Figure 4: Global Market Share of Autoimmune Disorder Therapies, by Drug Class, 2019
    • Figure 5: Global Market Share of Autoimmune Disorder Therapies, by Immunosuppressant Drug, 2019
    • Figure 6: Global Market for NSAIDs for Autoimmune Disorder Therapies, 2018-2024
    • Figure 7: Global Market for NSAIDs for Autoimmune Disorder Therapies, by Region, 2018-2024
    • Figure 8: Global Market for Autoimmune Disorder Therapies, by Immunosuppressant Drug, 2018-2024
    • Figure 9: Global Market Share of Autoimmune Disorder Therapies, by Immunosuppressant Drug, 2019
    • Figure 10: Global Market for Immunosuppressant Drugs for Autoimmune Disorder Therapies, by Region, 2018-2024
    • Figure 11: Global Market for Corticosteroids for Autoimmune Disorder Therapies, 2018-2024
    • Figure 12: Global Market for Corticosteroids for Autoimmune Disorder Therapies, by Region, 2018-2024
    • Figure 13: Global Market for Biologics for Autoimmune Disorder Therapies, 2018-2024
    • Figure 14: Global Market for Biologics for Autoimmune Disorder Therapies, by Region, 2018-2024
    • Figure 15: Global Market for Inhibitors for Autoimmune Disorder Therapies, 2018-2024
    • Figure 16: Global Market for Inhibitors for Autoimmune Disorder Therapies, by Region, 2018-2024
    • Figure 17: Global Market Share of Autoimmune Disorder Therapies, by Indication, 2019
    • Figure 18: Global Prevalence of Major Autoimmune Diseases, 2016 and 2017 Per 100,000
    • Figure 19: Global Market for Autoimmune Disorder Therapies for Type 1 Diabetes, 2018-2024
    • Figure 20: Global Market for Autoimmune Disorder Therapies for Type 1 Diabetes, by Region, 2018-2024
    • Figure 21: Global Market for Autoimmune Disorder Therapies for Rheumatoid Arthritis, 2018-2024
    • Figure 22: Global Market for Autoimmune Disorder Therapies for Rheumatoid Arthritis, by Region, 2018-2024
    • Figure 23: Global Market for Autoimmune Disorder Therapies for Psoriasis/Psoriatic Arthritis, 2018-2024
    • Figure 24: Global Market for Autoimmune Disorder Therapies for Psoriasis/Psoriatic Arthritis, by Region, 2018-2024
    • Figure 25: Global Market for Autoimmune Disorder Therapies for Multiple Sclerosis, 2018-2024
    • Figure 26: Global Market for Autoimmune Disorder Therapies for Multiple Sclerosis, by Region, 2018-2024
    • Figure 27: Global Market for Autoimmune Disorder Therapies for Inflammatory Bowel Disease, 2018-2024
    • Figure 28: Global Market for Autoimmune Disorder Therapies for Inflammatory Bowel Disease, by Region, 2018-2024
    • Figure 29: Global Market for Autoimmune Disorder Therapies for Systemic Lupus Erythematosus, 2018-2024
    • Figure 30: Global Market for Autoimmune Disorder Therapies for Systemic Lupus Erythematosus, by Region, 2018-2024
    • Figure 31: Global Market for Autoimmune Disorder Therapies for Other Autoimmune Diseases, 2018-2024
    • Figure 32: Global Market for Autoimmune Disorder Therapies for Other Autoimmune Diseases, by Region, 2018-2024
    • Figure 33: Global Market Share of Autoimmune Disorder Therapies, by Region, 2019
    • Figure 34: North American Market Share of Autoimmune Disorder Therapies, by Drug Class, 2019
    • Figure 35: North American Market Share of Autoimmune Disorder Therapies, by Immunosuppressant Drugs, 2019
    • Figure 36: North American Market Share of Autoimmune Disorder Therapies, by Indication, 2019
    • Figure 37: North American Market Share of Autoimmune Disorder Therapies, by Country, 2019
    • Figure 38: U.S. Market for Autoimmune Disorder Therapies, 2018-2024
    • Figure 39: Canadian Market for Autoimmune Disorder Therapies, 2018-2024
    • Figure 40: Mexican Market for Autoimmune Disorder Therapies, 2018-2024
    • Figure 41: European Market Share of Autoimmune Disorder Therapies, by Drug Class, 2019
    • Figure 42: European Market Share of Autoimmune Disorder Therapies, by Type of Immunosuppressant Drug, 2019
    • Figure 43: European Market Share of Autoimmune Disorder Therapies, by Indication, 2019
    • Figure 44: European Market Share of Autoimmune Disorder Therapies, by Country, 2019
    • Figure 45: German Market for Autoimmune Disorder Therapies, 2018-2024
    • Figure 46: French Market for Autoimmune Disorder Therapies, 2018-2024
    • Figure 47: U.K. Market for Autoimmune Disorder Therapies, 2018-2024
    • Figure 48: Italian Market for Autoimmune Disorder Therapies, 2018-2024
    • Figure 49: Spanish Market for Autoimmune Disorder Therapies, 2018-2024
    • Figure 50: Rest of Europe Market for Autoimmune Disorder Therapies, 2018-2024
    • Figure 51: Asia-Pacific Market Share of Autoimmune Disorder Therapies, by Drug Class, 2019
    • Figure 52: Asia-Pacific Market Share of Autoimmune Disorder Therapies, by Type of Immunosuppressant Drug, 2019
    • Figure 53: Asia-Pacific Market Share of Autoimmune Disorder Therapies, by Indication, 2019
    • Figure 54: Asia-Pacific Market Share of Autoimmune Disorder Therapies, by Country, 2019
    • Figure 55: Japanese Market for Autoimmune Disorder Therapies, 2018-2024
    • Figure 56: Chinese Market for Autoimmune Disorder Therapies, 2018-2024
    • Figure 57: Indian Market for Autoimmune Disorder Therapies, 2018-2024
    • Figure 58: Australian and New Zealand Market for Autoimmune Disorder Therapies, 2018-2024
    • Figure 59: Rest of Asia-Pacific Market for Autoimmune Disorder Therapies, 2018-2024
    • Figure 60: Rest of World Market Share of Autoimmune Disorder Therapies, by Drug Class, 2019
    • Figure 61: Rest of World Market Share of Autoimmune Disorder Therapies, by Type of Immunosuppressant Drug, 2019
    • Figure 62: Rest of World Market Share of Autoimmune Disorder Therapies, by Indication, 2019
    • Figure 63: Rest of World Market Share of Autoimmune Disorder Therapies, by Country/Region, 2019
    • Figure 64: Brazilian Market for Autoimmune Disorder Therapies, 2018-2024
    • Figure 65: Gulf Cooperation Council Countries Market for Autoimmune Disorder Therapies, 2018-2024
    • Figure 66: South African Market for Autoimmune Disorder Therapies, 2018-2024
    • Figure 67: Remaining Rest of World Countries Market for Autoimmune Disorder Therapies, 2018-2024
    • Figure 68: Global Market Share of Autoimmune Disorder Therapies, by Manufacturer, 2019
    • Figure 69: AbbVie Inc.: Annual Revenue, 2016-2019
    • Figure 70: AbbVie Inc.: Revenue Share, by Region/Country, 2019
    • Figure 71: AbbVie Inc.: Revenue Share, by Business Unit, 2019
    • Figure 72: Amgen Inc.: Annual Revenue, 2016-2019
    • Figure 73: Amgen Inc.: Revenue Share, by Region/Country, 2019
    • Figure 74: Amgen Inc.: Revenue Share, by Products, 2019
    • Figure 75: AstraZeneca: Annual Revenue, 2016-2019
    • Figure 76: AstraZeneca: Revenue Share, by Region/Country, 2019
    • Figure 77: AstraZeneca: Revenue Share, by Business Unit, 2019
    • Figure 78: Bayer AG: Annual Revenue, 2016-2019
    • Figure 79: Bayer AG: Revenue Share, by Region, 2019
    • Figure 80: Bayer AG: Revenue Share, by Business Unit, 2019
    • Figure 81: Bristol-Myers Squibb: Annual Revenue, 2016-2019
    • Figure 82: Bristol-Myers Squibb: Revenue Share, by Region/Country, 2019
    • Figure 83: Bristol-Myers Squibb: Revenue Share, by Brands, 2019
    • Figure 84: F. Hoffmann-La Roche Ltd.: Annual Revenue, 2016-2019
    • Figure 85: F. Hoffmann-La Roche Ltd.: Revenue Share in Pharmaceutical Segment, by Region/Country, 2019
    • Figure 86: F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Segment, 2019
    • Figure 87: Johnson & Johnson: Annual Revenue, 2016-2019
    • Figure 88: Johnson & Johnson: Revenue Share, by Region/Country, 2019
    • Figure 89: Johnson & Johnson: Revenue Share, by Business Unit, 2019
    • Figure 90: Mylan N.V.: Annual Revenue, 2016-2019
    • Figure 91: Mylan N.V.: Revenue Share, by Region, 2019
    • Figure 92: Mylan N.V.: Revenue Share, by Business Unit, 2019
    • Figure 93: Novartis AG.: Annual Revenue, 2015-2019
    • Figure 94: Novartis AG: Revenue Share, by Region/Country, 2019
    • Figure 95: Novartis AG: Revenue Share, by Business Segment, 2019
    • Figure 96: Pfizer Inc.: Annual Revenue, 2016-2019
    • Figure 97: Pfizer Inc.: Revenue Share, by Region/Country, 2019
    • Figure 98: Pfizer Inc.: Revenue Share, by Business Segment, 2019
    • Figure 99: Vertex Pharmaceuticals Inc.: Annual Revenue, 2016-2019
    • Figure 100: Vertex Pharmaceuticals Inc.: Research and Development Expense Annual Revenue, 2017-2019
    • Figure 101: Vertex Pharmaceuticals Inc.: Revenue Share, by Business Segment, 2019
目次
Product Code: PHM240A

Highlights:

The global market for autoimmune disorder therapies should grow from $53.2 billion in 2019 to $90.7 billion by 2024 with a compound annual growth rate (CAGR) of 11.2% for the period of 2019-2024.

Immunosuppressant drugs market for autoimmune disorder therapies should grow from $35.9 billion in 2019 to $63.2 billion by 2024 with a compound annual growth rate (CAGR) of 12.0% for the period of 2019-2024.

NSAIDs (non-steroidal anti-inflammatory drugs) market for autoimmune disorder therapies should grow from $17.4 billion in 2019 to $27.4 billion by 2024 with a compound annual growth rate (CAGR) of 9.6% for the period of 2019-2024.

Report Scope:

The report will provide details about autoimmune disorder therapies used in the treatment of autoimmune disease and how it has been influenced by the pandemic of COVID-19. This report will also highlight the current and future market potentiality of autoimmune disorder therapies with detailed analyses of the competitive environments between companies. Drivers, restraints, opportunities, pricing analysis, prevalence or incidence autoimmune disease and regulatory scenarios will also be covered. The report includes a market projection for 2024 and market shares for key players.

The report segments the market for autoimmune therapies based on drug class, indications and geography. Based on drug class, the market is segmented into immunosuppressant and NSAIDs. The immunosuppressant drug class is further segmented into corticosteroids, biologics and inhibitors. The market size includes drug class and its major brands on sale and serviceable in market. Based on indications, the market is segmented into type 1 diabetes, rheumatoid arthritis (RA), psoriasis/psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, systemic lupus erythematosus (SLE), and others (pernicious anemia, celiac disease, autoimmune vasculitis, myasthenia gravis, Hashimoto's thyroiditis, Sjogren's syndrome, Graves' disease, Addison's disease, etc.).

By geography, the market has been segmented into North America, Europe, the Asia-Pacific and the Rest of the World. A detailed analysis of major countries such as the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, Gulf Cooperation Council countries and South Africa will be covered in the regional segments. For market estimates, data will be provided for 2019 as the base year, with estimates for 2020 and forecast values for 2024.

Report Includes:

  • 30 data tables and 18 additional tables
  • An overview of the global markets for autoimmune disorder therapies
  • Estimation of the market size and analyses of market trends, with data from 2018, 2019 and projection of CAGR through 2024
  • Characterisation and quantification of autoimmune disorder therapies based on drug class, age group, and region
  • Impact analysis of COVID-19 pandemic on autoimmune disorder therapies market and highlights of the current and future market potential of these therapies
  • Evaluation of current market trends, market size, market forecast, and detailed analysis of drivers, challenges, and opportunities affecting market growth
  • Market share analysis of the key companies of the industry, their strategic profiling, their competitive landscape and their detailed company profiles, including AstraZeneca, Vertex Pharmaceuticals Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche AG (Roche), Pfizer Inc., and Johnson and Johnson

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Autoimmune Disorder Therapies
  • Biologics as Autoimmune Disorder Therapies
  • Trends in Autoimmune Disorder Therapies

Chapter 4: Market Dynamics

  • Market Drivers
  • Increasing Epidemiology of Autoimmune Diseases
  • Rise in the Geriatric Population
  • Rising Awareness of Autoimmune Diseases
  • New Therapeutic Pathway for Autoimmune and Inflammatory Disorders
  • Market Restraints
  • Side Effects of Therapeutics
  • High Cost of Autoimmune Disorder Therapies
  • Market Opportunities
  • Launch of New Therapeutics for Autoimmune Diseases
  • Growing use of Autoimmune Disorder Therapies for COVID-19 Patients

Chapter 5: Market Breakdown by Drug Class

  • Global Market for Autoimmune Disorder Therapies
  • NSAIDs
  • Market Size and Forecast
  • Market Analysis
  • Immunosuppressant Drugs
  • Market Size and Forecast
  • Market Analysis
  • Corticosteroids
  • Biologics
  • Inhibitors

Chapter 6: Market Breakdown by Indication

  • Global Market for Autoimmune Disorder Therapies by Indication
  • Type 1 Diabetes
  • Market Size and Forecast
  • Rheumatoid Arthritis
  • Market Size and Forecast
  • Psoriasis/Psoriatic Arthritis
  • Market Size and Forecast
  • Multiple Sclerosis
  • Market Size and Forecast
  • Inflammatory Bowel Disease
  • Market Size and Forecast
  • Systemic Lupus Erythematosus
  • Market Size and Forecast
  • Other Autoimmune Diseases
  • Market Size and Forecast

Chapter 7: Market Breakdown by Region

  • Global Market for Autoimmune Disorder Therapies by Region
  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia and New Zealand
  • Rest of Asia-Pacific
  • Rest of World
  • Market Analysis
  • Brazil
  • Gulf Cooperation Council Countries
  • South Africa
  • Remaining Rest of World Countries

Chapter 8: Impact of COVID-19

Chapter 9: Therapeutics Pipeline

Chapter 10: Competitive Landscape

  • Global Company Share Analysis
  • Mergers and Acquisitions
  • Agreements, Launches, Collaborations and Partnerships

Chapter 11: Company Profiles

  • ABBVIE INC.
  • AMGEN INC.
  • ASTRAZENECA
  • BAYER AG
  • BRISTOL-MYERS SQUIBB
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON
  • MYLAN N.V.
  • NOVARTIS AG
  • PFIZER INC.
  • VERTEX PHARMACEUTICALS INC.

Chapter 12: Appendix: Acronyms

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.